• Title/Summary/Keyword: Pharmacopoeia

Search Result 185, Processing Time 0.021 seconds

Clean Analysis Not to Use Harmful Solvent for TLC Identification Test of the Herbal Medicine (생약의 확인시험법에 대한 유해용매 대체시험법 설정)

  • Kim, Ji-Yeon;Park, Ju-Young;Shim, Young-Hoon;Cho, Chang-Hee;Lee, Jong-Hwa;Lee, Dong-Jin;Kim, Bo-Joon;Kim, Dong-Sup;Seong, Rack-Seon;Kim, Jong-Hwan;Lim, Sook;Shin, Jin-Seon;Jang, Seung-Yeup
    • Korean Journal of Pharmacognosy
    • /
    • v.41 no.2
    • /
    • pp.136-140
    • /
    • 2010
  • This study was carried out to utilize non-toxic solvents instead of harmful solvents for the TLC(Thin Layer Chromatography) identification test of herbal medicines. It is recommended not to use harmful solvent such as chloroform at a viewpoint of clean analysis. In this study, we revised the identification test of 10 items in the Korea Pharmacopoeia(KP) and the Korean Herbal Pharmacopoeia(KHP) such as Cornus officinalis S. containing the harmful solvents on the developing solvent and established identification test that is utilized non-toxic solvents by HPTLC(High Performance Thin Layer Chromatography).

Development of the Standard Analytical Methods for Compound Hawthorn Berry 60% Ethanol Extract, Ginkgo Biloba Leaf Extract and Garlic Oil Capsules (복방서양산사60%에탄올엑스.은행엽엑스.마늘유캡슐의 기준 및 시험법과 규격 설정)

  • Cho, Chang-Hee;Kim, Ji-Sun;Whang, Ji-Sang;Baek, Ju-Hyun;Park, Ju-Young;Shim, Young-Hoon;Seong, Rack-Seon;Kim, Dong-Sup;Lee, Jong-Phill;Lee, Joo-Hyeun;Sohn, Su-Jung
    • Korean Journal of Pharmacognosy
    • /
    • v.41 no.1
    • /
    • pp.67-72
    • /
    • 2010
  • In the recent version of the Korea Pharmacopoeia(KP) and the Korean Herbal Pharmacopoeia(KHP), there are 563 items(181 in KP, 381 in KHP) of herbal medicines including finished drugs. Also, approximately 507 items including herbal extracts and herbal medicinal products was published in the 3th edition of Korea Pharmaceutical Codex (KPC). These items help the persons working in the pharmaceutical manufacturing field to register the drug and in research fields to develop the new drug considering as a standard specifications. This study was carried out to establish standard analytical methods for 'Compound Hawthorn Berry 60% Ethanol Extract, Ginkgo Biloba Leaf Extract and Garlic Oil Capsules' in the 3th edition of Korea Pharmaceutical Codex. Ginkgo flavonoid and terpene lactone were employed as reference compounds for analytical method. Analytical methods established in this study could be applied to a reasonable and unified quality control of G. biloba leaf extract and hawthorn berry extract.

Studies on the Crude Drugs of Atractylodis Species (출류(朮類) 대조 생약에 관한 연구)

  • Kim, Ho-Hyun;Chon, In-Ju;Kang, In-Ho;Ham, In-Hye;Ze, Keam-Ryon;Whang, Wan-Kyunn;Cho, Hyoung-Kwon
    • Korean Journal of Pharmacognosy
    • /
    • v.34 no.2 s.133
    • /
    • pp.123-127
    • /
    • 2003
  • Atrartylodis Rhizoma(蒼朮)'s origin plants are Atratylodes lancea and A. Chinensis in Chinese, Japanese and Korean pharmacopoeia. A. Japonica is only indigenous in Korea, it is actually used as Atractylodis Rhizoma in Korean market. A. lancea is used in Hunan province, China and A. Chinensis is used in Hubei province, China. It is impossible to distinguish with species differency as macro- and micro-morphology. We tried to distinguish with species differency by HPLC and GC-Mass spectra. Atractylone(mw. 216) which is a marker compound in Atractylodis Rhizoma Alba(白朮) was detected in A. japonica. Atractylodin (mw.182) was detected in A. lancea and two eudesmadien derivatives (mw. 204) were detected in A. chinensis. HPLC chromatogram showed the same patterns. As a result, we propose that A. japonica will be added as Atractylodis Rhizoma (蒼朮)'s origin plant in Korean Pharmacopoeia. Atractylodis Rhizoma Alba(白朮)'s origin plants are A. macrocephala in China, and A. Japonica and A. ovata in Korea and Japan. In GC-Mass analysis, all samples showed same patterns and the main compound was atractylone.

Studies on the advanced model for quality control system of oriental medicine (한약재 품질관리체계 선진화 모형에 관한 연구)

  • Choi Sun-Mi;Yoon Yoo-Sik;Choi Hwan-Soo;Lee Mi-Young;Shin Soon-Shik;Lee Key-Nam;Chung Hee-Jin;Kim Hee-Soo;Sung Hyun-Jea
    • Journal of Society of Preventive Korean Medicine
    • /
    • v.4 no.2
    • /
    • pp.193-204
    • /
    • 2000
  • In this study, advanced model for quality control of oriental medicine and methods for practice was suggested through literature inspection, analysis of foreign system such as China and Japan, survey analysis on the current system, quality analysis of randomly selected oriental medicine samples, and intensive discussions among oriental medicine specialists 1. The quality of oriental medicine should be consistently controlled by Ministry of Health and Welfare form its cultivation or import to its circulation process to final consumer 2. All oriental medicines should be circulated as standardized goods which should be marked by lot numbers. The packing material and Packing size should be liberalized. The qualify should be differentialized though free competition among makers. 3. Realistic standards for pesticide, heavy metal and decolorant should be established though long-term monitoring process according to each oriental medicine's origin, therapeutic part, cultivation area, harvesting time, and cultivation method. 4. Ministry of Health and Welfare should educate oriental medicine's quality control personnel regularly or on demand, and establish specialist pool. Ministry of Health and Welfare should also establish oriental medicine information system to provide informations about quality of domestic or foreign oriental medicinal raw materials. 5. The government should provide information about foreign of oriental medicine market to importers. Quality of imported oriental medicine should be inspected before its customs clearance, and all imported oriental medicine should be circulated by standardized oriental medicine makers. 6. Oriental medicine's pharmacopoeia should be Published to provide quality standard of oriental medicine and improve it.

  • PDF

Determination of diphencyprone and its photo-degradation product incompounded preparations using HPLC

  • Cho, Chong Woon;Kim, Kyung Tae;Park, Miyeon;Kim, Jin Seog;Lee, Jinbok;Kang, Jong Seong
    • Analytical Science and Technology
    • /
    • v.31 no.5
    • /
    • pp.179-184
    • /
    • 2018
  • Diphencyprone (DPCP) is frequently used as a compounded preparation in dermatology for the treatment of alopecia and recalcitrant warts based on the immune reaction of skin allergy. However, DPCP is a non-recognized agent in Pharmacopoeia, because there are no criteria or analytical method for quality control of its powder and formulation. DPCP is unstable under light irradiation because as it easily decomposes to diphenylacetylene (DPA). This study aims to develop a simultaneous HPLC analytical method for analyzing DPCP and DPA in the raw materials and compounded preparation. The method required a C18 column ($250{\times}4.6mm$, $5{\mu}m$) at $40^{\circ}C$ with a mobile phase of (A) 0.01 M phosphoric acid in water and (B) acetonitrile at UV 220 nm. DPA conversion to DPCP in the powder and compounded preparations was accelerated after light exposure for 60 min. In addition, this resulted in different patterns depending on the wavelength of light and the formulation. That is, DPCP in compounded preparation was more unstable than that in the powder. However, the DPCP formulation in amber bottles was observed to remain stable, although the measured concentrations of DPCP were somewhat different from the nominal concentration of the compounded preparations. The control of the exact concentration is required for effective disease treatment, depending on the state of the patient. In conclusion, these results will be useful for the recognition of DPCP in Pharmacopoeia and new DPCP formulation development to prevent photodecomposition.

Cultivation and Characteristics of Licorice F1 (Glycyrrhiza glabra × G. uralensis) Lines

  • Lee, Sang-Hoon;Kim, Yeon Bok;Lee, Jeong-Min;Lee, Jeong-Hoon;Park, Chung-Berm;Bang, Jae-Wook;Choi, Hae-Woon;Hur, Yoonkang;Park, Chun-Geon
    • Horticultural Science & Technology
    • /
    • v.35 no.2
    • /
    • pp.276-286
    • /
    • 2017
  • Licorice, a traditional Korean medicinal plant, is recognized for its main active ingredient, glycyrrhizin. The level of glycyrrhizin in Chinese licorice (Glycyrrhiza uralensis) is lower than the reference level (2.5%) set by the Korean Pharmacopoeia, reducing its value as a medicinal herb. In this study, we aimed to overcome this problem by generating an interspecific licorice hybrid by crossing European licorice (G. glabra) with Chinese licorice, resulting in the production of 32 $F_1$ lines. A comparison of genetic traits revealed variations in glycyrrhizin content among lines, ranging from 1.5 to 5.6%, with a mean value of 3.2%; these values are higher than that of the parental plants. Additionally, 25 lines (78.1%) had a glycyrrhizin content greater than 2.5%, which is higher than the reference level set by the Korean Pharmacopoeia. Four of these lines had glycyrrhizin levels higher than the WHO recommended level of 4.0%. A comparison of phenotypic characteristics showed that the leaves of the hybrids possessed all of the characteristics of European and Chinese licorice; however, the stems of most hybrids had characteristics of European licorice. Finally, we determined the genetic distances of 34 samples of Glycyrrhiza plants (parents, 32 $F_1$ lines) by random amplified polymorphic DNA (RAPD); the $F_1$ lines showed a close genetic distance. We plan to develop to a cultivar using five of these lines (glycyrrhizin content < 4.0%).

Systematic Botanical Survey of Traditional Herbal Medicines Listed in the Official Drug Compendia(Pharmacopoeia and Natural Drug Standards) of Korea, China and Japan (한(韓) 중(中) 일(日)의 공정서(公定書)(약전(藥典) 및 규격집(規格集))에 수재(收載)된 전통천연약물(傳統天然藥物)의 품질(品質)에 관한 조사(調査) (I) -기원(起源)에 관한 분류학적(分類學的) 검토(檢討)-)

  • Park, Sang-Hi;Youm, Jeong-Rok;Chang, Il-Moo
    • Korean Journal of Pharmacognosy
    • /
    • v.22 no.2
    • /
    • pp.112-123
    • /
    • 1991
  • Traditional drugs(herbal and animal drugs) of Korea, China and Japan have developed essentially from the same origin, since the traditional medicine of three countries has been originated from ancient China. Due to different geographical locations and discrepancy of plant resources of the traditional drugs, some divergency in terms of systematic botany in traditional drug materials has appeared in the three countries. Present report aims to survey traditional herbal drugs that have been called same traditional names in three countries, but they are actually different with respect to systematic botanical view-point. The official drug compendia(pharmacopoeia and natural drug standards) of three countries were subject to examination. Survey was conducted by the following categories. Traditional drugs were listed under same name, however, 1) they belong to different genus; 7 traditional herbal drugs were listed. 2) they belong to same genus, but different species; 24 traditional herbal drugs were found. 3) a variety of related species are used; 15 traditional drugs were listed. 4) actually same plant, but taxonomical name is differently called and/or different parts of plant are used; 10 traditional drugs were counted. 5) animal drugs belong to one of the above categories; 7 traditional animal drugs were found. Total 63 traditional drugs(herbal and animal) were found to comprise different taxonomical names when the official drug compendia of Korea, China and Japan were examined.

  • PDF

Review of the taxonomy and CITES species lists in musk deer (CITES 분류에 의한 사향(麝香)의 기원 동물 분류 및 특성에 대한 고찰)

  • Chang, Mun Seog;Kim, Do Rim;Kim, Hyun Chul;Park, Seong Kyu
    • Herbal Formula Science
    • /
    • v.24 no.4
    • /
    • pp.323-333
    • /
    • 2016
  • Objectives : The purpose of this study was to investigate musk deer in taxonomic status and genus species. We investigated the characteristic of musk deer for medicinal usages. Methods : To identifications of musk deer on the taxonomic status and genus species, the literary investigation were conducted on the Korean, China, and Japan pharmacopoeia and published herbal books, CITES Species Lists too. Results : Musk deer placement in a separate family status is the Moschidae. M. chrysogaster Hodgson and M. sifanicus Przewalski was the same species. So, Alpine musk deer revised M. chrysogaster Hodgson[=M. sifanicus Przewalski]. Geographic distribution of M. moschiferus L. divided Sibirica group and himalaica group. Group himalaica contains three subspecies: Korean musk deer(M. moschiferus parvipes Hol.), Chinese musk deer(M. chrysogaster Hodgson), and Himalayan musk deer(M. leucogaster Hodgson). The genetic divergence between M. moschiferus L. and other species was clearly distinguished from the others. M. berezovskii Flerove was less than the others. However, the divergence among M. chrysogaster Hodgson, M. fuscus Li, and M. leucogaster Hodgson were quite low. Musk deers are mostly distributed around the high-plateau. Moschus were from Nepal, Bhutan, Russia, China. Forest musk deer(M. berezovskii Flerove) farming was conducted in China from 1950s. In the Korean hebal pharmacopoeia, Moschus include l-muscone($C_{16}H_{30}O$ : 238.40) over 2% for quantitative test. Conclusions : There are three species of musk deer, Siberian musk deer(M. moschiferus L.), forest musk deer(M. berezovskii Flerove), and Alpine musk deer(M. chrysogaster Hodgson) for medicinal usages.

Determination of the quantity of tolperisone hydrochloride in tablets by high performance liquid chromatography

  • Truong, Quoc-Ky;Mai, Xuan-Lan;Kim, Dae Hyun;Kim, Jeon Kyung;Kang, Jong-Seong;Woo, Mi Hee;Na, Dong-Hee;Chun, In-Koo;Kim, Kyeong Ho
    • Analytical Science and Technology
    • /
    • v.30 no.1
    • /
    • pp.32-38
    • /
    • 2017
  • In attempt to contribute in official monographs of Korean Pharmacopoeia, an HPLC method was developed and fully validated for the determination of tolperisone hydrochloride in tablets which have never been published in other forgein Pharmacopoeia. Analysis was carried out in an ODS column ($250{\times}4.6mm$ I.D., $5{\mu}m$) with common solvents include acetonitrile and ammonium hydrophosphate buffer as mobile phase. The assay was validated according to International Conference on Harmonization (ICH) guidelines. The method has good linearity in the range of $5-200{\mu}g/mL$ tolperisone. Intra-day precision varied between 0.04 and 0.10 %. Relative standard deviations of inter-day precision ranged between 0.43 and 1.24 % for peak area. The percentage recovery of the tolperisone ranged between 99.8 and 101.2 % in material. Recoveries in tablets were ranged between 98.7 and 100.8 %, thus confirmed the suitability of method for estimation of tolperisone hydrochloride in tablet dosage form.

Distribution of Medicinal Plants and Vascular Plants Growing at Yangsan Region of Nakdong River, Korea (낙동강 하류 양산천 일대에 자생하는 관속식물상 및 약용식물의 분포 특성)

  • Ahn, Young Sup;Lee, Jeong Hoon;An, Tae Jin;Park, Chung Berm;Moon, Sung Gi;Kim, Myeong Seok;Seo, Joung Seok;Lee, Cheol Hee
    • Korean Journal of Medicinal Crop Science
    • /
    • v.20 no.6
    • /
    • pp.421-433
    • /
    • 2012
  • This study was carried out to survey the vascular plants in 6 regions including around Hopo-Bridge of Yangsan region at waterfronts of Nakdong river, Korea. Distributed plants were surveyed from April to November, 2011. The vascular plants in 6 regions (around Mulgeum-chuisujang, Mulgeum-station, Jeungsan-ri, Hopo-bridge, Kumoh-bridge and lower part of Yangsan-stream) were total 135 taxa of 3 divisions, 4 classes, 37 orders, 66 families, 116 genera, 114 species, 2 subspecies and 19 varieties. The most number of species is Campanulales of 14.1% in Dicotyledoneae of 81.5% among total species. Regional distribution of species is mainly around Mulgeum-chuisujang and Jeungsan-ri as 61% among total species, and other regions is in 24 ~ 44%. Ecologically, there were herbaceous plants 75% and woody plants 25%, and 9 species of aquatic plants in herbaceous plants. Medicinal (herbal) plants included in KP (The Korean Pharmacopoeia) and KHP (The Korean Herbal Pharmacopoeia) were 56 species including Platycodon grandiflorum (Jacq.) A. De Candolle, Peucedanum japonicum Thunberg and etc., and folk herb plants were 14 species including Metaplexis japonica Makino, Commelina communis Linn$\acute{e}$ and etc. among total 135 species.